Coeptis Therapeutics (COEP) Competitors $14.80 -0.21 (-1.37%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. CTNM, ALEC, MREO, CADL, SCPH, NMRA, GALT, IMMP, ALLO, and JBIOShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Contineum Therapeutics (CTNM), Alector (ALEC), Mereo BioPharma Group (MREO), Candel Therapeutics (CADL), scPharmaceuticals (SCPH), Neumora Therapeutics (NMRA), Galectin Therapeutics (GALT), Prima BioMed (IMMP), Allogene Therapeutics (ALLO), and Jade Biosciences (JBIO). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Contineum Therapeutics Alector Mereo BioPharma Group Candel Therapeutics scPharmaceuticals Neumora Therapeutics Galectin Therapeutics Prima BioMed Allogene Therapeutics Jade Biosciences Contineum Therapeutics (NASDAQ:CTNM) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk. Is CTNM or COEP more profitable? Contineum Therapeutics' return on equity of -29.75% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -29.75% -28.08% Coeptis Therapeutics N/A -201.73%-108.46% Do insiders & institutionals hold more shares of CTNM or COEP? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 11.3% of Contineum Therapeutics shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor CTNM or COEP? In the previous week, Coeptis Therapeutics had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 0 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 1.24 beat Coeptis Therapeutics' score of 0.65 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Contineum Therapeutics Positive Coeptis Therapeutics Positive Which has more volatility and risk, CTNM or COEP? Contineum Therapeutics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Do analysts prefer CTNM or COEP? Contineum Therapeutics currently has a consensus target price of $22.20, suggesting a potential upside of 97.86%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Contineum Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better valuation and earnings, CTNM or COEP? Coeptis Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M6.29-$42.26M-$2.20-5.10Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.55 SummaryContineum Therapeutics beats Coeptis Therapeutics on 10 of the 15 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.31M$3.41B$6.08B$10.51BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-2.5522.5084.1027.01Price / SalesN/A481.27607.14130.56Price / CashN/A46.9737.8662.13Price / Book9.1910.4112.236.56Net Income-$10.88M-$52.47M$3.32B$276.88M7 Day Performance-5.76%1.72%0.46%0.68%1 Month Performance17.42%13.86%7.73%3.86%1 Year Performance271.73%12.07%70.73%34.96% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.6036 of 5 stars$14.80-1.4%N/A+277.6%$71.31MN/A-2.552Short Interest ↑CTNMContineum Therapeutics2.5049 of 5 stars$11.39+2.8%$22.20+94.9%-24.8%$319.40MN/A-5.1831Positive NewsALECAlector4.0597 of 5 stars$3.07-3.5%$4.17+35.7%-38.1%$310.72M$81.13M-2.65270Positive NewsMREOMereo BioPharma Group1.9428 of 5 stars$1.95-3.0%$7.40+279.5%-55.7%$310.05M$500K-27.8640News CoverageAnalyst DowngradeCADLCandel Therapeutics2.5963 of 5 stars$5.63+2.9%$20.00+255.2%-12.9%$309.09M$120K-8.1660SCPHscPharmaceuticals4.1536 of 5 stars$5.75+1.4%$7.78+35.4%N/A$306.41M$49.97M-3.1830High Trading VolumeNMRANeumora Therapeutics2.0024 of 5 stars$1.86-1.6%$7.14+284.0%-89.3%$306.08MN/A-1.18108GALTGalectin Therapeutics1.192 of 5 stars$4.77+7.4%$6.00+25.8%+92.0%$305.57MN/A-7.459News CoverageIMMPPrima BioMed1.0398 of 5 stars$2.08+6.7%$7.00+236.5%+2.9%$305.32MN/A0.002,021High Trading VolumeALLOAllogene Therapeutics2.9989 of 5 stars$1.35-2.2%$8.44+525.5%-55.4%$299.54MN/A-1.22310JBIOJade Biosciences2.0323 of 5 stars$9.04-1.1%$16.00+77.0%N/A$294.98MN/A-0.3020High Trading Volume Related Companies and Tools Related Companies Contineum Therapeutics Alternatives Alector Alternatives Mereo BioPharma Group Alternatives Candel Therapeutics Alternatives scPharmaceuticals Alternatives Neumora Therapeutics Alternatives Galectin Therapeutics Alternatives Prima BioMed Alternatives Allogene Therapeutics Alternatives Jade Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
